FMA
GBT

FNY Managed Accounts’s Global Blood Therapeutics, Inc. GBT Stock Holding History

FNY Managed Accounts’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2,130
Closed -$49.1K – 311
2016
Q3 		$49.1K Sell
2,130
-98,570
-98% -$1.88M 0.04% 216
2016
Q2 		$1.67M Buy
+100,700
New +$2.03M 1.53% 14

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

FNY Managed Accounts's GBT Position: Q4 2016 in Review

FNY Managed Accounts sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2016, closing a stake of 2,130 shares — an estimated $49.1K sold.

FNY Managed Accounts first reported a position in GBT in Q2 2016 and held it in 2 quarters. The position peaked at $1.67M in Q2 2016. 96 funds tracked by Wall St. Rank hold GBT as of Q4 2016.

  • FNY Managed Accounts reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • FNY Managed Accounts sold 2,130 Global Blood Therapeutics, Inc. shares in Q4 2016, an estimated $49.1K.
  • FNY Managed Accounts first reported a position in Global Blood Therapeutics, Inc. in Q2 2016 and held it in 2 quarters.
  • FNY Managed Accounts's Global Blood Therapeutics, Inc. position peaked at $1.67M in Q2 2016.
  • 96 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2016.

Based on FNY Managed Accounts's 13F filing for Q4 2016, filed 8 Feb 2017.